Monday 20 December 2021

Biogen on Monday cut in half the price of its Alzheimer's drug Aduhlem in an effort to boost lackluster sales that stemmed in part from controversy over its price. The company said Aduhelm will cost $28,200 per year for an average weight patient

Biogen on Monday cut in half the price of its Alzheimer's drug Aduhlem in an effort to boost lackluster sales that stemmed in part from controversy over its price. The company said Aduhelm will cost $28,200 per year for an average weight patient submitted by /u/DoremusJessup
[link] [comments]


from Health https://ift.tt/3EipMGS
via IFTTT

No comments:

Post a Comment